Biotech companies are lining up for initial public offerings in a bullish sign for the US listing market
Unlock the Editor’s Digest for free Roula Khalaf, editor of the FT, selects her favorite stories in this weekly newsletter. Alumis and Upstream Bio, two U.S. startups developing drugs for inflammatory diseases, have filed for initial public offerings as dozens of biotech companies prepare to go public this year, according to people familiar with the … Read more
